bioMérieux, Open Innovation and Partnerships, La Balme Les Grottes, France.
Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO, USA.
Nat Rev Microbiol. 2020 May;18(5):299-311. doi: 10.1038/s41579-020-0327-x. Epub 2020 Feb 13.
Antimicrobial resistance (AMR) is a major threat to human health worldwide, and the rapid detection and quantification of resistance, combined with antimicrobial stewardship, are key interventions to combat the spread and emergence of AMR. Antimicrobial susceptibility testing (AST) systems are the collective set of diagnostic processes that facilitate the phenotypic and genotypic assessment of AMR and antibiotic susceptibility. Over the past 30 years, only a few high-throughput AST methods have been developed and widely implemented. By contrast, several studies have established proof of principle for various innovative AST methods, including both molecular-based and genome-based methods, which await clinical trials and regulatory review. In this Review, we discuss the current state of AST systems in the broadest technical, translational and implementation-related scope.
抗微生物药物耐药性(AMR)是全球范围内对人类健康的主要威胁,快速检测和定量耐药性,加上抗菌药物管理,是对抗 AMR 传播和出现的关键干预措施。抗微生物药物敏感性测试(AST)系统是一组有助于进行 AMR 和抗生素敏感性表型和基因型评估的诊断过程。在过去的 30 年中,仅开发和广泛实施了少数几种高通量 AST 方法。相比之下,有几项研究已经为各种创新的 AST 方法建立了原理验证,包括基于分子和基于基因组的方法,这些方法正在等待临床试验和监管审查。在这篇综述中,我们从最广泛的技术、转化和实施相关的角度讨论了 AST 系统的现状。